IDEXX Laboratories, Inc.

Healthcare · Medical - Diagnostics & Research

Overall research band Mixed

Quality Strong

Valuation Very weak

Balance sheet Exceptional

Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

IDEXX Laboratories, Inc. is a global healthcare company headquartered in Westbrook, Maine, specializing in the development, manufacture, and distribution of diagnostic products and services. Its primary customers include companion animal veterinary practices, livestock and poultry producers, dairy operations, and water quality testing organizations. The company operates through divisions such as the Companion Animal Group (CAG), Water Quality Products, and Livestock, Poultry, and Dairy (LPD). IDEXX offers veterinary diagnostic instruments, consumables, rapid assay kits, reference laboratory services, practice management software, and diagnostic imaging solutions. It also provides water testing products for detecting microbiological contaminants, including Colilert, Colilert-18, Colisure, Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray. Additional offerings include health monitoring and diagnostic solutions for biomedical research and human point-of-care diagnostics.

The current research profile is Fallen Quality, with weak market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Business quality is the strongest visible dimension. Check valuation before treating that strength as an investment conclusion.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC45.4%Model input; read with the evidence status and period context.

Operating margin31.6%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years7.6%Model input; read with the evidence status and period context.

FCF margin24.5%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.